Press releases
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
More ▼
Key statistics
On Friday, Atara Biotherapeutics Inc (AT2:STU) closed at 0.4789, 143.47% above the 52 week low of 0.1967 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.4789 |
---|---|
High | 0.4789 |
Low | 0.4789 |
Bid | 0.4543 |
Offer | 0.49 |
Previous close | 0.4786 |
Average volume | 0.00 |
---|---|
Shares outstanding | 120.42m |
Free float | 109.22m |
P/E (TTM) | -- |
Market cap | 61.53m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼